Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2421-2433

  Primiano, Michael J ^a   Lefker, Bruce A ^a   Bowman, Michael R ^a   Bree, Andrea G ^a   Hubeau, Cedric ^a   Bonin, Paul D ^a   Mangan, Matthew ^b,c   Dower, Ken ^a   Monks, Brian G ^b,d   Cushing, Leah ^a   Wang, Stephen ^a   Guzova, Julia ^a   Jiao, Aiping ^a   Lin, Lih Ling ^a   Latz, Eicke ^b,c,d   Hepworth, David ^a   Hall, J Perry ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 456773; CRYOPYRIN; IMIDAZOQUINOLINE DERIVATIVE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CYTOKINE; FUSED HETEROCYCLIC RINGS; MCC-950; SULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DERMATITIS; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SECRETION; RESPIRATORY TRACT INFLAMMATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DERMATITIS; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PNEUMONIA; SIGNAL TRANSDUCTION; SULFONES;

EID: 84988936950     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600035     Document Type: Article

References (56)

1. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140: 821-832.
2. Pétrilli, V., C. Dostert, D. A. Muruve, and J. Tschopp. 2007. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19: 615-622.
3. Latz, E., T. S. Xiao, and A. Stutz. 2013. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13: 397-411.
4. Guo, H., J. B. Callaway, and J. P. Ting. 2015. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21: 677-687.
5. Yazdi, A. S., and S. K. Drexler. 2013. Regulation of interleukin 1a secretion by inflammasomes. Ann. Rheum. Dis. 72(Suppl. 2): ii96-ii99.
6. Willingham, S. B., I. C. Allen, D. T. Bergstralh, W. J. Brickey, M. T. Huang, D. J. Taxman, J. A. Duncan, and J. P. Ting. 2009. NLRP3 (NALP3, cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and-independent pathways. J. Immunol. 183: 2008-2015.
7. Gross, O., A. S. Yazdi, C. J. Thomas, M. Masin, L. X. Heinz, G. Guarda, M. Quadroni, S. K. Drexler, and J. Tschopp. 2012. Inflammasome activators induce interleukin-1a secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36: 388-400.
8. Masters, S. L., E. Latz, and L. A. O'Neill. 2011. The inflammasome in atherosclerosis and type 2 diabetes. Sci. Transl. Med. 3: 81ps17.
9. Lorenz, G., M. N. Darisipudi, and H. J. Anders. 2014. Canonical and noncanonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol. Dial. Transplant. 29: 41-48.
10. Franklin, B. S., L. Bossaller, D. De Nardo, J. M. Ratter, A. Stutz, G. Engels, C. Brenker, M. Nordhoff, S. R. Mirandola, A. Al-Amoudi, et al. 2014. The adaptor ASC has extracellular and "prionoid" activities that propagate inflammation. Nat. Immunol. 15: 727-737.
11. Baroja-Mazo, A., F. Martín-Sánchez, A. I. Gomez, C. M. Martínez, J. Amores-Iniesta, V. Compan, M. Barbera-Cremades, J. Yagüe, E. Ruiz-Ortiz, J. Antón, et al. 2014. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 15: 738-748.
12. Dinarello, C. A., A. Simon, and J. W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11: 633-652.
13. De Nardo, D., C. M. De Nardo, and E. Latz. 2014. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am. J. Pathol. 184: 42-54.
14. Turner, C. M., N. Arulkumaran, M. Singer, R. J. Unwin, and F. W. Tam. 2014. Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol. 15: 21.
15. Keyel, P. A. 2014. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine 69: 136-145.
16. Agostini, L., F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp. 2004. NALP3 forms an IL-1b-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20: 319-325.
17. Miyamae, T. 2012. Cryopyrin-associated periodic syndromes: diagnosis and management. Paediatr. Drugs 14: 109-117.
18. Hoffman, H. M. 2009. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin. Biol. Ther. 9: 519-531.
19. Dinarello, C. A., and J. W. van der Meer. 2013. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 25: 469-484.
20. Baldwin, A. G., D. Brough, and S. Freeman. 2015. Inhibiting the inflammasome: a chemical perspective. J. Med. Chem. 59: 1691-1710.
21. Perregaux, D. G., P. McNiff, R. Laliberte, N. Hawryluk, H. Peurano, E. Stam, J. Eggler, R. Griffiths, M. A. Dombroski, and C. A. Gabel. 2001. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. 299: 187-197.
22. Coll, R. C., A. A. Robertson, J. J. Chae, S. C. Higgins, R. Munoz-Planillo, M. C. Inserra, I. Vetter, L. S. Dungan, B. G. Monks, A. Stutz, et al. 2015. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21: 248-255.
23. Laliberte, R. E., D. G. Perregaux, L. R. Hoth, P. J. Rosner, C. K. Jordan, K. M. Peese, J. F. Eggler, M. A. Dombroski, K. F. Geoghegan, and C. A. Gabel. 2003. Glutathione S-transferase Omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1b posttranslational processing. J. Biol. Chem. 278: 16567-16578.
24. Urban, F. J., V. John Jasys, J. W. Raggon, R. A. Buzon, P. D. Hill, J. F. Eggler, and J. D. Weaver. 2003. Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an anti-inflammatory agent. Synth. Commun. 33: 2029-2043.
25. Tsuboi, K., D. A. Bachovchin, A. E. Speers, T. P. Spicer, V. Fernandez-Vega, P. Hodder, H. Rosen, and B. F. Cravatt. 2011. Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance. J. Am. Chem. Soc. 133: 16605-16616.
26. Zhao, Y., J. Yang, J. Shi, Y. N. Gong, Q. Lu, H. Xu, L. Liu, and F. Shao. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477: 596-600.
27. Hornung, V., F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, and E. Latz. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9: 847-856.
28. Hett, E. C., L. H. Slater, K. G. Mark, T. Kawate, B. G. Monks, A. Stutz, E. Latz, and D. T. Hung. 2013. Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat. Chem. Biol. 9: 398-405.
29. Fitz, L. J., C. DeClercq, J. Brooks, W. Kuang, B. Bates, D. Demers, A. Winkler, K. Nocka, A. Jiao, R. M. Greco, et al. 2012. Acidic mammalian chitinase is not a critical target for allergic airway disease. Am. J. Respir. Cell Mol. Biol. 46: 71-79.
30. Lamkanfi, M., J. L. Mueller, A. C. Vitari, S. Misaghi, A. Fedorova, K. Deshayes, W. P. Lee, H. M. Hoffman, and V. M. Dixit. 2009. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187: 61-70.
31. Griffiths, R. J., E. J. Stam, J. T. Downs, and I. G. Otterness. 1995. ATP induces the release of IL-1 from LPS-primed cells in vivo. J. Immunol. 154: 2821-2828.
32. Pan, Q., J. Mathison, C. Fearns, V. V. Kravchenko, J. Da Silva Correia, H. M. Hoffman, K. S. Kobayashi, J. Bertin, E. P. Grant, A. J. Coyle, et al. 2007. MDP-induced interleukin-1b processing requires Nod2 and CIAS1/NALP3. J. Leukoc. Biol. 82: 177-183.
33. Kanneganti, T. D., N. Ozören, M. Body-Malapel, A. Amer, J. H. Park, L. Franchi, J. Whitfield, W. Barchet, M. Colonna, P. Vandenabeele, et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233-236.
34. Hara, H., K. Tsuchiya, I. Kawamura, R. Fang, E. Hernandez-Cuellar, Y. Shen, J. Mizuguchi, E. Schweighoffer, V. Tybulewicz, and M. Mitsuyama. 2013. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat. Immunol. 14: 1247-1255.
35. Yan, Y., W. Jiang, T. Spinetti, A. Tardivel, R. Castillo, C. Bourquin, G. Guarda, Z. Tian, J. Tschopp, and R. Zhou. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38: 1154-1163.
36. Shah, F., and N. Greene. 2014. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space. Chem. Res. Toxicol. 27: 86-98.
37. Sipes, N. S., M. T. Martin, P. Kothiya, D. M. Reif, R. S. Judson, A. M. Richard, K. A. Houck, D. J. Dix, R. J. Kavlock, and T. B. Knudsen. 2013. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem. Res. Toxicol. 26: 878-895.
38. Baliwag, J., D. H. Barnes, and A. Johnston. 2015. Cytokines in psoriasis. Cytokine 73: 342-350.
39. Johnston, A., X. Xing, A. M. Guzman, M. Riblett, C. M. Loyd, N. L. Ward, C. Wohn, E. P. Prens, F. Wang, L. E. Maier, et al. 2011. IL-1F5,-F6,-F8, and-F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186: 2613-2622.
40. Carlström, M., A. K. Ekman, S. Petersson, P. Söderkvist, and C. Enerbäck. 2012. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp. Dermatol. 21: 932-937.
41. Wagner, E. F., H. B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler. 2010. Psoriasis: what we have learned from mouse models. Nat. Rev. Rheumatol. 6: 704-714.
42. Flutter, B., and F. O. Nestle. 2013. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 43: 3138-3146.
43. Dai, X., K. Sayama, M. Tohyama, Y. Shirakata, Y. Hanakawa, S. Tokumaru, L. Yang, S. Hirakawa, and K. Hashimoto. 2011. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. J. Allergy Clin. Immunol. 127: 806-814 e801-804. doi:10.1016/j.jaci.2010.12.006.
44. Iyer, S. S., W. P. Pulskens, J. J. Sadler, L. M. Butter, G. J. Teske, T. K. Ulland, S. C. Eisenbarth, S. Florquin, R. A. Flavell, J. C. Leemans, and F. S. Sutterwala. 2009. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. USA 106: 20388-20393.
45. Nakamura, Y., L. Franchi, N. Kambe, G. Meng, W. Strober, and G. Núnez. 2012. Critical role for mast cells in interleukin-1b-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 37: 85-95.
46. Nakamura, Y., N. Kambe, M. Saito, R. Nishikomori, Y. G. Kim, M. Murakami, G. Núnez, and H. Matsue. 2009. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. [Published erratum appears in 2009 J. Exp. Med. 206: 1205.] J. Exp. Med. 206: 1037-1046.
47. Cho, K. A., J. W. Suh, K. H. Lee, J. L. Kang, and S. Y. Woo. 2012. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1b by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 24: 147-158.
48. Rabeony, H., M. Pohin, P. Vasseur, I. Petit-Paris, J. F. Jégou, L. Favot, E. Frouin, M. A. Boutet, F. Blanchard, D. Togbe, et al. 2015. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome. Eur. J. Immunol. 45: 2847-2857.
49. Walter, A., M. Schäfer, V. Cecconi, C. Matter, M. Urosevic-Maiwald, B. Belloni, N. Schönewolf, R. Dummer, W. Bloch, S. Werner, et al. 2013. Aldara activates TLR7-independent immune defence. Nat. Commun. 4: 1560.
50. Willart, M. A., K. Deswarte, P. Pouliot, H. Braun, R. Beyaert, B. N. Lambrecht, and H. Hammad. 2012. Interleukin-1a controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 209: 1505-1517.
51. Idzko, M., H. Hammad, M. van Nimwegen, M. Kool, M. A. Willart, F. Muskens, H. C. Hoogsteden, W. Luttmann, D. Ferrari, F. Di Virgilio, et al. 2007. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med. 13: 913-919.
52. Kool, M., M. A. Willart, M. van Nimwegen, I. Bergen, P. Pouliot, J. C. Virchow, N. Rogers, F. Osorio, C. Reis e Sousa, H. Hammad, and B. N. Lambrecht. 2011. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34: 527-540.
53. Müller, T., R. P. Vieira, M. Grimm, T. Dürk, S. Cicko, R. Zeiser, T. Jakob, S. F. Martin, B. Blumenthal, S. Sorichter, et al. 2011. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am. J. Respir. Cell Mol. Biol. 44: 456-464.
54. Besnard, A. G., N. Guillou, J. Tschopp, F. Erard, I. Couillin, Y. Iwakura, V. Quesniaux, B. Ryffel, and D. Togbe. 2011. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 66: 1047-1057.
55. Ather, J. L., K. Ckless, R. Martin, K. L. Foley, B. T. Suratt, J. E. Boyson, K. A. Fitzgerald, R. A. Flavell, S. C. Eisenbarth, and M. E. Poynter. 2011. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J. Immunol. 187: 64-73.
56. Allen, I. C., C. M. Jania, J. E. Wilson, E. M. Tekeppe, X. Hua, W. J. Brickey, M. Kwan, B. H. Koller, S. L. Tilley, and J. P. Ting. 2012. Analysis of NLRP3 in the development of allergic airway disease in mice. J. Immunol. 188: 2884-2893.